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The prevention of infectious diseases is a major goal for global healthcare and vaccines are still among the best 
preventive tools. 
 
The recent Ebola virus outbreak has challenged the vaccine industry to boost the speed to market and process 
development activities for new vaccines. To be able to cope with infectious disease outbreaks, our company 
developed an intensified cell and virus culture process using PER.C6® cells and AdVac™ platform. In our 
intensified process, perfusion bioreactors are used to increase Adeno vector titers while minimizing capital 
investments. To further increase readiness and flexibility for manufacturability, we improved the current process 
by substituting the classical cell culture seed train with an innovative concept called LVHD (Large volume high 
density) where the seed train can be generated from a single bag of cells at high density reducing significantly 
the time needed for the final cell culture. 
 
In the current study the LVHD expansion train in comparison to the classic roller bottle expansion was evaluated 
in regard to Cost of Goods, facility footprint and operational flexibility. Moreover, the Adeno vector drug 
substances obtained from the two processes were compared.  
 
Finally, the robustness and consistency of our LVHD seed train will be shown by using Monte Carlo simulation 
approach. 
 
 
 
